iBio Inc (IBIO)
1.76
+0.04
(+2.33%)
USD |
NYAM |
Apr 26, 16:00
1.76
0.00 (0.00%)
After-Hours: 20:00
iBio SG&A Expense (Quarterly): 2.961M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.961M |
September 30, 2023 | 3.547M |
June 30, 2023 | 2.609M |
March 31, 2023 | 3.525M |
December 31, 2022 | 7.794M |
September 30, 2022 | 5.088M |
June 30, 2022 | 6.891M |
March 31, 2022 | 5.316M |
December 31, 2021 | 5.372M |
September 30, 2021 | 4.175M |
June 30, 2021 | 6.646M |
March 31, 2021 | 5.313M |
December 31, 2020 | 5.665M |
September 30, 2020 | 5.365M |
June 30, 2020 | 3.167M |
March 31, 2020 | 2.979M |
December 31, 2019 | 2.581M |
September 30, 2019 | 2.986M |
June 30, 2019 | 3.224M |
March 31, 2019 | 2.844M |
December 31, 2018 | 3.393M |
September 30, 2018 | 2.871M |
June 30, 2018 | 2.995M |
March 31, 2018 | 2.605M |
December 31, 2017 | 2.587M |
Date | Value |
---|---|
September 30, 2017 | 2.498M |
June 30, 2017 | 2.894M |
March 31, 2017 | 2.837M |
December 31, 2016 | 2.351M |
September 30, 2016 | 2.469M |
June 30, 2016 | 2.176M |
March 31, 2016 | 2.403M |
December 31, 2015 | 1.684M |
September 30, 2015 | 1.422M |
June 30, 2015 | 1.448M |
March 31, 2015 | 1.222M |
December 31, 2014 | 1.302M |
September 30, 2014 | 1.05M |
June 30, 2014 | 1.945M |
March 31, 2014 | 0.951M |
December 31, 2013 | 1.051M |
September 30, 2013 | 0.249M |
June 30, 2013 | 0.952M |
March 31, 2013 | 1.229M |
December 31, 2012 | 1.039M |
September 30, 2012 | 1.023M |
June 30, 2012 | 1.443M |
March 31, 2012 | 1.246M |
December 31, 2011 | 1.745M |
September 30, 2011 | 1.189M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.581M
Minimum
Dec 2019
7.794M
Maximum
Dec 2022
4.484M
Average
4.175M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Lixte Biotechnology Holdings Inc | 0.8768M |
PAVmed Inc | 11.72M |
Avalo Therapeutics Inc | 2.676M |
Imunon Inc | 2.415M |
Ocugen Inc | 5.155M |